Company
Arecor Therapeutics PLC
LON:AREC
Arecor Therapeutics plc is a clinical stage biotech company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, obesity and other cardiometabolic diseases. Arecor’s research and development activity is focused on its two proprietary insulin candidates, AT278, an ultra-concentrated, ultra-rapid-acting insulin (500U/mL), and AT290, a concentrated, ultra-rapid-acting insulin (200U/mL). These insulins have been designed to enable the next generation of longer wear, miniaturised and fully closed loop automated insulin delivery (AID) systems, and have the potential to be the only insulins in development with the profile to achieve this. These next generation AID systems in combination with Arecor’s insulins have the potential to reduce treatment burden and improve outcomes for people living with both type 1 and type 2 diabetes who require intensive insulin therapy (IIT). Broadening access to next generation AID systems also represents a significant commercial opportunity. In the United States, there are approximately four million people with diabetes on IIT, who are candidates for AID. This translates to an insulin revenue market of approximately $5 billion, of which Arecor has identified the people with the highest unmet need for its insulins represent approximately $3 billion market opportunity in the US alone. Arecor is also developing a novel oral delivery platform for peptides with its first validation target a GLP-1 receptor agonist. Current treatment options are mostly limited to injectable therapies, due to the low oral bioavailability of orally delivered peptides and it is this challenge that Arecor is seeking to overcome. The Company is quoted on AIM (AIM: AREC) and is based in Cambridge, UK.
123 stories · page 1 of 2
Arecor Therapeutics doses first type 2 diabetes patient in ultra-rapid insulin trial
Arecor said it has dosed the first patient in its second phase 1 trial of rapid-acting insulin, AT278
Arecor Therapeutics says unit chooses US firm Syneos for European roll-out
Syneos will provide commercial support and build healthcare sector awareness of Tetris’ flagship diabetes product Ogluo
Archive
Small Cap Feast - Arecor Therapeutics, CentralNic Group, Crossword Cybersecurity, and more...
22 November 2022*A corporate client of Hybridan LLP** Arranged by most recent first*** Alphabetically arrangedDish of the dayJoiners:No joiners today.Leavers:No leavers today.What’s cooking in the IPO kitchen?**Kistos Holdings plc, intends
Arecor Therapeutics gets trial green light; secures Japan and Korea patent protection
The company gained similar IP protection in the US earlier this year
Arecor inks formulation deal with global chemicals and pharma company
The unnamed partner will fund the work and has the option to acquire rights to the new formulation
Arecor Therapeutics launches Ogluo injector pen in Germany
Designed for those with severe hypoglycaemia or low blood sugar it is Ogluo’s first launch in the EU
Arecor hails results from study of rapid-acting insulin
This second phase I study pitted AT247 against the gold standard treatments for diabetes
Arecor Therapeutics reports positive results from insulin trial
Sarah Howell, chief executive officer of Arecor- said: "By enabling reduced injection volumes and fewer injections per day, whilst offering the potential for improved blood glucose control with its superior PK/PD profile, AT278 has the pote
Arecor Therapeutics says AT247 trial results can be 'significant inflexion point'
Arecor recently acquired Tetris Pharma to broaden its reach
Arecor Therapeutics wins European patent protection for high concentration version of world's top selling drug
The company used its Arestat technology to create a high-concentration version of Humira
UK pharma’s global status at risk due to skills shortages
Research and discovery fields suffering most from drop in applications
Arecor Therapeutics unveils Tetris acquisition plans funded by £6mln placing
This next piece in the puzzle for Arecor is designed to propel the business towards commercial success
Arecor Therapeutics expects to seal revenue-generating partnerships in the second half
The group, which is developing ultra-rapid acting insulin treatments, provided the progress report as part of a business update
Arecor Therapeutics to give presentation on Phase I trial of its AT278 insulin product at EASD
"AT278 has the potential to be the first, and potentially only, ultra-concentrated (500U/mL) yet ultra-rapid acting insulin,” said chief executive Sarah Howell